GW Pharmaceuticals PLC- Company Profile (NASDAQ:GWPH)

About GW Pharmaceuticals PLC- (NASDAQ:GWPH)

GW Pharmaceuticals PLC- logoGW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the Company's commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Symbol: NASDAQ:GWPH
  • CUSIP: N/A
  • Web:
  • Market Cap: $2.73 billion
  • Outstanding Shares: 25,308,000
Average Prices:
  • 50 Day Moving Avg: $113.16
  • 200 Day Moving Avg: $118.92
  • 52 Week Range: $79.62 - $137.88
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -23.43
  • P/E Growth: 0.37
Sales & Book Value:
  • Annual Revenue: $9.87 million
  • Price / Sales: 276.41
  • Book Value: $17.98 per share
  • Price / Book: 6.00
  • EBIDTA: ($156,480,000.00)
  • Net Margins: -702.90%
  • Return on Equity: -20.07%
  • Return on Assets: -17.00%
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 9.92%
  • Quick Ratio: 9.81%
  • Average Volume: 289,340 shs.
  • Beta: 2.72
  • Short Ratio: 6.03

Frequently Asked Questions for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

What is GW Pharmaceuticals PLC-'s stock symbol?

GW Pharmaceuticals PLC- trades on the NASDAQ under the ticker symbol "GWPH."

How were GW Pharmaceuticals PLC-'s earnings last quarter?

GW Pharmaceuticals PLC- (NASDAQ:GWPH) announced its quarterly earnings results on Tuesday, May, 9th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.50) by $0.20. The company earned $2.04 million during the quarter, compared to the consensus estimate of $2.07 million. GW Pharmaceuticals PLC- had a negative net margin of 702.90% and a negative return on equity of 20.07%. The business's revenue was down 23.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.06) earnings per share. View GW Pharmaceuticals PLC-'s Earnings History.

Where is GW Pharmaceuticals PLC-'s stock going? Where will GW Pharmaceuticals PLC-'s stock price be in 2017?

10 brokers have issued 1-year price objectives for GW Pharmaceuticals PLC-'s stock. Their predictions range from $40.00 to $208.00. On average, they expect GW Pharmaceuticals PLC-'s stock price to reach $147.22 in the next twelve months. View Analyst Ratings for GW Pharmaceuticals PLC-.

What are analysts saying about GW Pharmaceuticals PLC- stock?

Here are some recent quotes from research analysts about GW Pharmaceuticals PLC- stock:

  • 1. According to Zacks Investment Research, "GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. " (5/15/2017)
  • 2. Cantor Fitzgerald analysts commented, "NDA Filing Expected Mid-2017. GWPH expects to complete its filing in the U.S. shortly and noted two key portions in progress: 1) an integrated safety analysis of over 1,500 treated patients from clinical studies and the expanded access program, and 2) manufacturing data from the company’s manufacturing processes, including scaled materials. These elements will be the two determining factors of the timing of the NDA submission, which is expected in the middle of the year. Following the U.S. submission, GW expects to submit its MAA filing in 2H17 and plans to meet with the EMA in the near term. Pre-commercialization Activities Intensify. Greenwich Biosciences, the U.S. subsidiary of GW, is progressing with a pre-commercial strategy of expanding its team for the drug launch of Epidiolex. GW guided for a commercial team consisting of 15 medical-science liaisons by the end of 2017 and a sales force of 50-60 sales representatives to reach 4,000-5,000 targeted U.S. physicians. In addition, the company has begun to engage payors on awareness of patient need, Epidiolex, and pricing. We believe these efforts will set a meaningful foundation for Epidiolex’s commercial launch, which we estimate will initiate in 2018. Model Update. Following F2Q17 financial results, we have updated our model to reflect recent quarterly results and future expectations of operational expenditures." (5/9/2017)
  • 3. Maxim Group analysts commented, "Epilepsy remains a challenging indication to treat, with over a third of patients (>750k patients in the U.S.) who are inadequately controlled despite several antiepileptic drugs (market of >$5B) taken concurrently. GW’s lead product, Epidiolex, an orphan drug designated oral CBD (cannabidiol), showed positive results in three P3 trials for Dravet (DS) and Lennox-Gastaut syndromes (LGS)." (4/20/2017)

Who are some of GW Pharmaceuticals PLC-'s key competitors?

Who owns GW Pharmaceuticals PLC- stock?

GW Pharmaceuticals PLC-'s stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (5.94%), Janus Capital Management LLC (2.52%), Bank of America Corp DE (2.44%), Jennison Associates LLC (1.85%), Redmile Group LLC (1.32%) and Morgan Stanley (1.20%). View Institutional Ownership Trends for GW Pharmaceuticals PLC-.

Who sold GW Pharmaceuticals PLC- stock? Who is selling GW Pharmaceuticals PLC- stock?

GW Pharmaceuticals PLC-'s stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, FMR LLC, Goldman Sachs Group Inc., Bank of America Corp DE, Redmile Group LLC, Credit Suisse AG, Janus Capital Management LLC and Advisors Asset Management Inc.. View Insider Buying and Selling for GW Pharmaceuticals PLC-.

Who bought GW Pharmaceuticals PLC- stock? Who is buying GW Pharmaceuticals PLC- stock?

GW Pharmaceuticals PLC-'s stock was purchased by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Renaissance Technologies LLC, Nomura Holdings Inc., Pictet Asset Management Ltd., Clough Capital Partners L P, Morgan Stanley, Victory Capital Management Inc. and Van ECK Associates Corp. View Insider Buying and Selling for GW Pharmaceuticals PLC-.

How do I buy GW Pharmaceuticals PLC- stock?

Shares of GW Pharmaceuticals PLC- can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of GW Pharmaceuticals PLC- stock cost?

One share of GW Pharmaceuticals PLC- stock can currently be purchased for approximately $107.80.

Analyst Ratings

Consensus Ratings for GW Pharmaceuticals PLC- (NASDAQ:GWPH) (?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.70)
Consensus Price Target: $147.22 (36.57% upside)

Analysts' Ratings History for GW Pharmaceuticals PLC- (NASDAQ:GWPH)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/9/2017Cantor FitzgeraldReiterated RatingBuy$208.00HighView Rating Details
4/20/2017Maxim GroupInitiated CoverageBuy -> Buy$135.00MediumView Rating Details
2/22/2017Goldman Sachs Group IncReiterated RatingBuy$185.00N/AView Rating Details
2/6/2017Cowen and CompanySet Price TargetBuy$135.00N/AView Rating Details
2/7/2017Piper Jaffray CompaniesSet Price TargetBuy$147.00N/AView Rating Details
11/3/2016Leerink SwannReiterated RatingBuy$162.00N/AView Rating Details
9/25/2016Morgan StanleyBoost Price TargetOverweight$152.00 -> $160.00N/AView Rating Details
8/26/2016Numis Securities LtdUpgradeSell -> HoldN/AView Rating Details
7/18/2016Bank of America CorpReiterated RatingBuy$153.00N/AView Rating Details
6/27/2016Janney Montgomery ScottInitiated CoverageSell$40.00N/AView Rating Details
3/14/2016Roth CapitalBoost Price TargetBuy$130.00 -> $160.00N/AView Rating Details
(Data available from 5/23/2015 forward)


Earnings History for GW Pharmaceuticals PLC- (NASDAQ:GWPH)
Earnings by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)
Earnings History by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/20173/31/2017($1.50)($1.70)$2.07 million$2.04 millionViewListenView Earnings Details
2/7/2017Q117($1.35)($0.77)$1.85 million$2.54 millionViewListenView Earnings Details
12/5/2016Q416($1.48)($0.89)$2.85 million$2.16 millionViewListenView Earnings Details
2/10/2016Q116($1.53)($0.10)$4.61 million$5.40 millionViewListenView Earnings Details
12/7/2015Q415($1.38)($0.85)$15.00 million$5.60 millionViewN/AView Earnings Details
8/6/2015Q315($1.30)($1.60)$12.82 million$13.55 millionViewN/AView Earnings Details
5/11/2015Q215($1.23)($0.58)$11.38 million$9.43 millionViewListenView Earnings Details
2/4/2015Q115($0.91)($0.26)$12.12 million$12.40 millionViewN/AView Earnings Details
12/2/2014Q414($0.46)$0.02$9.15 million$12.03 millionViewN/AView Earnings Details
8/6/2014Q314($0.62)($0.66)$12.88 million$13.00 millionViewN/AView Earnings Details
5/7/2014Q114($0.30)$0.49$12.48 million$12.55 millionViewN/AView Earnings Details
2/4/2014Q413($0.34)($0.02)$11.54 million$7.49 millionViewN/AView Earnings Details
11/19/2013Q4($0.19)($0.29)ViewListenView Earnings Details
8/5/2013Q313($0.11)$0.02$10.71 million$11.04 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for GW Pharmaceuticals PLC- (NASDAQ:GWPH)
2017 EPS Consensus Estimate: ($8.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.80)($1.80)($1.80)
Q2 20171($1.98)($1.98)($1.98)
Q3 20172($2.34)($2.18)($2.26)
Q4 20171($2.49)($2.49)($2.49)
(Data provided by Zacks Investment Research)


Dividend History for GW Pharmaceuticals PLC- (NASDAQ:GWPH)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for GW Pharmaceuticals PLC- (NASDAQ:GWPH)
No insider trades for this company have been tracked by


Headline Trends for GW Pharmaceuticals PLC- (NASDAQ:GWPH)
Latest Headlines for GW Pharmaceuticals PLC- (NASDAQ:GWPH)
DateHeadline logoGW Pharmaceuticals - Cannabis Cannabinoid - Seeking Alpha - May 21 at 8:17 AM logoGW Pharmaceuticals Announces Research & Development Management Appointments - GlobeNewswire (press release) - May 16 at 5:29 PM logoGW Pharmaceuticals PLC- (GWPH) Downgraded to "Sell" at Zacks Investment Research - May 16 at 12:34 AM logoETFs with exposure to GW Pharmaceuticals Plc : May 15, 2017 - May 15 at 5:09 PM logoQ3 2017 EPS Estimates for GW Pharmaceuticals PLC- Cut by Leerink Swann (GWPH) - May 15 at 8:14 AM logoGW Pharmaceuticals PLC- (GWPH) Downgraded by TheStreet - May 15 at 12:02 AM logoGW Pharmaceuticals PLC- (GWPH) Receives Average Rating of "Buy" from Analysts - May 13 at 12:26 AM logoAnalysts' Actions -- Chemours, Incyte, Visteon, Toyota and More - May 12 at 6:17 PM logoGW Pharmaceuticals Plc :GWPH-US: Earnings Analysis: Q2, 2017 By the Numbers : May 12, 2017 - May 12 at 6:17 PM logoGW Pharmaceuticals PLC- (GWPH) Releases Earnings Results, Misses Expectations By $0.20 EPS - May 11 at 12:04 AM logoAnalyst: GW Pharma Has Started Laying The Groundwork For Taking Epidiolex To Market - May 10 at 12:36 PM logoGW Pharmaceuticals PLC- (GWPH) Rating Reiterated by Cantor Fitzgerald - May 9 at 9:14 PM logoGW Pharmaceuticals plc Reports Fiscal Second Quarter 2017 Financial Results and Operational Progress - May 9 at 5:24 PM logoRelative Strength Alert For GW Pharmaceuticals - May 8 at 5:18 PM logoInvestor Network Invites You to the GW Pharmaceuticals Second Quarter 2017 Earnings Conference Call and Webcast Live on Tuesday, May 9, 2017 - May 8 at 5:18 PM logoGW Pharmaceuticals PLC- (GWPH) Earns Media Impact Score of 0.30 - May 3 at 9:42 PM logo$2.69 Million in Sales Expected for GW Pharmaceuticals PLC- (GWPH) This Quarter - May 3 at 3:38 PM logo3 Charts That Show Why the Marijuana Stock Boom Could Continue - May 2 at 10:13 AM logoZacks: Brokerages Expect GW Pharmaceuticals PLC- (GWPH) Will Announce Earnings of -$1.50 Per Share - May 1 at 1:56 PM logoGW Pharmaceuticals PLC- (GWPH) Earns Daily Media Impact Score of -0.12 - April 30 at 10:51 AM logoGW Pharmaceuticals PLC- (GWPH) Earns Media Impact Rating of 0.11 - April 27 at 11:46 PM logoGW Pharma: Favorable Developments For Epilepsy Solution - Seeking Alpha - April 27 at 8:19 AM logoMarket Pipeline for Fragile X Syndrome H1 2017 Therapeutics Products Development, Companies and Drugs Profiled at - April 25 at 11:01 AM logoGW Pharmaceuticals PLC- (GWPH) Receives News Sentiment Score of -0.22 - April 23 at 9:06 AM logoBetter Know a Marijuana Stock: Insys Therapeutics - April 21 at 5:35 PM logoGW Pharmaceuticals PLC- (GWPH) Given "Buy" Rating at Maxim Group - April 20 at 6:18 PM logo2 New Ways To Invest In Marijuana Stocks: Cannabis ETFs - April 20 at 5:42 PM logoOp-Ed: The US is falling behind other countries—like Canada—on marijuana - April 20 at 5:42 PM logoGW Pharma (GWPH) Highlights New Epidiolex Data Released by AAN - April 19 at 11:41 AM logoGW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Highlight New Epidiolex® (cannabidiol) Data Released by the American Academy of Neurology - April 18 at 5:11 PM logoGW Pharmaceuticals PLC- (GWPH) Given Average Recommendation of "Buy" by Brokerages - April 18 at 12:33 AM logoYikes! These 5 Marijuana Stocks Lost a Combined $193 Million in 2016 - April 17 at 11:10 AM logo3 Marijuana Stocks You Can Still Buy Without (Too Much) Fear - April 16 at 10:29 AM logoGW Pharmaceuticals PLC- (GWPH) Earning Somewhat Critical Press Coverage, Study Shows - April 16 at 10:17 AM logoGW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences to Present Data on Epidiolex® (cannabidiol) at the 2017 American Academy of Neurology Annual Meeting - April 13 at 10:35 AM logoGW Pharmaceuticals PLC- (GWPH) Given Daily Media Sentiment Score of 0.04 - April 13 at 8:50 AM logoGW Pharmaceuticals: Up 188%, But I'm Not Selling - Seeking Alpha - April 11 at 12:10 PM logoZacks: Brokerages Anticipate GW Pharmaceuticals PLC- (GWPH) Will Post Earnings of -$1.50 Per Share - April 10 at 8:12 AM logoGW Pharmaceuticals: Past The Clinical Stage? - Seeking Alpha - April 7 at 10:31 PM logoGW Pharmaceuticals PLC- (GWPH) Short Interest Down 11.0% in March - April 7 at 6:06 PM logoGW Pharmaceuticals is Now Oversold (GWPH) - April 7 at 10:09 AM logoGottlieb Should Consider Cannabis As He Makes Opioids His Top Priority - April 7 at 10:09 AM logoGW Pharmaceuticals Announces Epidiolex® Receives Orphan Drug Designation from the European Medicines Agency for the Treatment of Lennox-Gastaut Syndrome - March 29 at 10:54 AM logoFDA Allows Ziopharm's Brain Cancer Drug Trial - March 27 at 5:13 PM logoGW Pharmaceuticals PLC- (GWPH) Receives Consensus Rating of "Buy" from Brokerages - March 23 at 12:14 PM logoOpko Gets Orphan Status for Genetic Disorder Drug - March 22 at 5:47 PM logo15 Things You Need to Know Before Investing in Marijuana Stocks - March 20 at 7:10 PM logoWhy Education Could Be The Biggest Beneficiary Of Cannabis Legalization - March 16 at 3:39 PM logoForm 6-K GW PHARMACEUTICALS PLC For: Mar 14 - - March 15 at 5:53 PM logoBiotech Innovations Drive Cannabinoid-Based Pharmaceutical Market Growth - March 15 at 8:57 AM



GW Pharmaceuticals PLC- (GWPH) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by Staff